Becton Dickinson & Co
BDX
180.16
-0.14
-0.08%
Becton Dickinson & Co
US · BDX
#450 by market cap
Listed 1970
180.16
-0.14
-0.08%
Live - 5344 symbols - heartbeat 139s ago
· 2026-10-08 08:05
Pre-market
180.29
+0.07%
After-hours
180.16
0.00%
Overnight
179.27
-0.49%
- Market cap
- 49.07B
- P/E (TTM)i
- 54.43
- P/Bi
- 2.01
- EPSi
- 5.82
- Div yieldi
- 2.33%
- 52W posi
- 83%
Reader sentiment
Are you bullish or bearish on BDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.00, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.24% YoY
Margins
- Gross margin
- 45.44%
- Operating margin
- 13.67%
- Net margin
- 7.68%
Key ratios & quality
- Enterprise valuei
- 67.61B
- Altman Z-Scorei
- 2.00
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.98B | 17.29B | 16.07B | 19.13B | 18.87B | 19.37B | 20.18B | 21.84B |
| Gross profit | 7.27B | 8.29B | 6.80B | 8.63B | 8.48B | 8.17B | 9.13B | 9.93B |
| Selling & admin expenses | 4.02B | 4.33B | 4.19B | 4.72B | 4.71B | 4.72B | 4.86B | 5.28B |
| Research & development | 1.00B | 1.06B | 1.04B | 1.28B | 1.26B | 1.24B | 1.19B | 1.27B |
| Operating profit | 2.25B | 2.24B | 1.21B | 2.43B | 2.48B | 2.42B | 2.86B | 2.99B |
| Pretax profit | 1.17B | 1.18B | 414.00M | 1.69B | 1.78B | 1.66B | 2.01B | 1.88B |
| Tax | 862.00M | -57.00M | 62.00M | 88.00M | 148.00M | 132.00M | 300.00M | 203.00M |
| Net profit | 311.00M | 1.23B | 874.00M | 2.09B | 1.78B | 1.48B | 1.71B | 1.68B |
| Basic EPS | 1 | 4 | 3 | 7 | 6 | 5 | 6 | 6 |
| Diluted EPS | 0.60 | 3.94 | 2.71 | 6.85 | 5.88 | 4.94 | 5.86 | 5.82 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.48B | 4.73B | 8.30B | 5.25B | 4.71B | 4.98B |
| Gross profit | 1.86B | 2.24B | 4.03B | 2.41B | 2.15B | 2.32B |
| Selling & admin expenses | 1.12B | 1.16B | 1.84B | 1.39B | 1.21B | 1.26B |
| Research & development | 232.00M | 230.00M | 559.00M | 306.00M | 249.00M | 258.00M |
| Operating profit | 477.00M | 835.00M | 1.30B | 662.00M | 626.00M | 752.00M |
| Pretax profit | 201.00M | 569.00M | 975.00M | 393.00M | 39.00M | 554.00M |
| Tax | 43.00M | 118.00M | 52.00M | 11.00M | 76.00M | 102.00M |
| Net profit | 308.00M | 574.00M | 493.00M | 382.00M | -311.00M | 377.00M |
| Basic EPS | 1 | 2 | 2 | 1 | -1 | 1 |
| Diluted EPS | 1.07 | 2.00 | 1.72 | 1.34 | -1.11 | 1.37 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 7.41B | 6.66B | 8.97B | 8.84B | 8.14B | 8.68B | 10.47B | 9.26B |
| Cash & ST investments | 1.16B | 566.00M | 2.85B | 2.30B | 1.01B | 1.42B | 2.16B | 649.00M |
| Inventory | 2.45B | 2.58B | 2.74B | 2.74B | 3.22B | 3.27B | 3.84B | 3.89B |
| Total assets | 53.90B | 51.77B | 54.01B | 53.88B | 52.93B | 52.78B | 57.29B | 55.33B |
| Total current liabilities | 7.22B | 5.66B | 5.84B | 6.63B | 7.81B | 6.64B | 8.96B | 8.31B |
| Short-term debt | 2.60B | 1.31B | 706.00M | 500.00M | 2.18B | 1.14B | 2.17B | 1.56B |
| Long-term debt | 18.89B | 18.08B | 17.22B | 17.11B | 13.89B | 14.74B | 17.94B | 17.62B |
| Total liabilities | 32,910,000,000.00 | 30,683,000,000.00 | 30,247,000,000.00 | 30,203,000,000.00 | 27,652,000,000.00 | 26,983,000,000.00 | 31,397,000,000.00 | 29,935,000,000.00 |
| Total equity | 20.99B | 21.08B | 23.77B | 23.68B | 25.28B | 25.80B | 25.89B | 25.39B |
| Retained earnings | 12.60B | 12.91B | 12.79B | 13.83B | 15.16B | 15.54B | 16.14B | 16.62B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 8.67B | 9.00B | 9.26B | 9.19B | 8.01B | 8.14B |
| Cash & ST investments | 683.00M | 757.00M | 649.00M | 751.00M | 816.00M | 709.00M |
| Inventory | 3.72B | 3.95B | 3.89B | 4.09B | 3.36B | 3.32B |
| Total assets | 54.47B | 54.90B | 55.33B | 54.84B | 50.83B | 50.73B |
| Total current liabilities | 7.69B | 8.16B | 8.31B | 8.76B | 8.51B | 9.40B |
| Short-term debt | 1.60B | 1.81B | 1.56B | 2.62B | 2.57B | 3.30B |
| Long-term debt | 17.67B | 17.53B | 17.62B | 16.92B | 14.71B | 13.51B |
| Total liabilities | 29,226,000,000.00 | 29,429,000,000.00 | 29,935,000,000.00 | 29,559,000,000.00 | 26,700,000,000.00 | 26,315,000,000.00 |
| Total equity | 25.24B | 25.47B | 25.39B | 25.28B | 24.13B | 24.42B |
| Retained earnings | 16.15B | 16.43B | 16.62B | 16.70B | 17.39B | 17.51B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.87B | 3.33B | 3.54B | 4.65B | 2.63B | 2.99B | 3.80B | 3.43B |
| Depreciation & amortization | 1.98B | 2.25B | 2.12B | 2.23B | 2.23B | 2.29B | 2.29B | 2.46B |
| Free cash flow | 1.97B | 2.37B | 2.77B | 3.45B | 1.66B | 2.12B | 3.07B | 2.67B |
| Dividends paid | -927.00M | -984.00M | -1.03B | -1.05B | -1.08B | -1.11B | -1.10B | -1.20B |
| Stock buybacks / issuance | 0 | 0 | 2.92B | -1.75B | -500.00M | 0 | -500.00M | -1.00B |
| Ending cash balance | 1.24B | 590.00M | 2.92B | 2.39B | 1.16B | 1.48B | 1.86B | 851.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 163.00M | 1.22B | 1.36B | 656.00M | 600.00M | 651.00M |
| Depreciation & amortization | 524.00M | 575.00M | 756.00M | 614.00M | 520.00M | 563.00M |
| Free cash flow | 49.00M | 1.06B | 978.00M | 548.00M | 475.00M | 508.00M |
| Dividends paid | -298.00M | -299.00M | -297.00M | -299.00M | -290.00M | -286.00M |
| Stock buybacks / issuance | 0 | 0 | -250.00M | -250.00M | -2.00B | 0 |
| Ending cash balance | 681.00M | 727.00M | 851.00M | 1.03B | 1.02B | 863.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 0.94 | 5.14 | 3.42 | 8.44 | 6.90 | 5.58 | 6.60 | 6.54 |
| ROA %i | 0.35 | 2.05 | 1.45 | 3.71 | 3.16 | 2.69 | 3.10 | 2.98 |
| ROIC %i | 1.69 | 3.71 | 2.99 | 5.86 | 4.94 | 4.32 | 4.60 | 4.84 |
| 5-year avg ROE %i | 11.80 | 8.13 | 6.54 | 5.59 | 4.97 | 5.90 | 6.19 | 6.81 |
| EBIT margin %i | 11.76 | 10.50 | 8.84 | 13.39 | 11.56 | 10.91 | 12.55 | 11.42 |
| FCF / sales %i | 12.33 | 13.71 | 15.94 | 16.87 | 8.80 | 10.92 | 15.22 | 12.23 |
| Current ratioi | 1.03 | 1.18 | 1.54 | 1.33 | 1.04 | 1.31 | 1.17 | 1.11 |
| Quick ratioi | 0.48 | 0.51 | 0.90 | 0.70 | 0.41 | 0.60 | 0.58 | 0.44 |
| Debt / assetsi | 39.88 | 37.46 | 33.20 | 32.68 | 30.35 | 30.09 | 35.10 | 34.67 |
| LT debt / equityi | 90.01 | 85.77 | 72.48 | 72.27 | 54.93 | 57.13 | 69.30 | 69.40 |
| Interest coveragei | 2.66 | 2.84 | 2.87 | 5.78 | 5.48 | 4.68 | 4.80 | 4.07 |
| Revenue CAGR (3Y) %i | 15.84 | 11.47 | 9.95 | 6.18 | 2.96 | 6.42 | 1.79 | 4.99 |
| Net income CAGR (3Y) %i | -23.51 | 8.10 | -7.38 | 88.77 | 13.00 | 19.30 | -6.59 | -1.93 |
| FCF CAGR (3Y) %i | 20.25 | 8.34 | 14.96 | 20.58 | -11.23 | -8.60 | -3.83 | 17.18 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.89 | 6.17 | 6.54 | 6.96 | 4.61 | 3.78 |
| ROA %i | 2.76 | 2.87 | 2.98 | 3.21 | 2.16 | 1.78 |
| ROIC %i | 4.34 | 4.50 | 4.84 | 5.15 | 3.84 | 3.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 10.93 | 11.68 | 11.42 | 11.76 | 11.27 | 10.98 |
| FCF / sales %i | 12.41 | 11.92 | 12.23 | 12.00 | 13.75 | 11.16 |
| Current ratioi | 1.13 | 1.10 | 1.11 | 1.05 | 0.94 | 0.87 |
| Quick ratioi | 0.48 | 0.45 | 0.44 | 0.37 | 0.36 | 0.33 |
| Debt / assetsi | 35.38 | 35.23 | 34.67 | 35.63 | 33.99 | 33.13 |
| LT debt / equityi | 69.99 | 68.82 | 69.40 | 66.91 | 60.94 | 55.34 |
| Interest coveragei | 3.81 | 4.08 | 4.07 | 4.22 | 4.10 | 4.19 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Medical Essentials is the largest reported line at 33.61% of revenue, across 4 reported segments.
- No single line clears half of revenue; Interventional is next at 28.38%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Medical Essentials33.61%
Interventional28.38%
Connected Care24.56%
BioPharma Systems13.45%
Quote time 2026-10-08 08:05:13 · For reference only, not investment advice and not tailored to your situation.